

**SURGICAL APPLICATION FORM**

**Name of the Attendee of the Course : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Name of the Home institution : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**City:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Email: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Part I – General evaluation of the centre**

|  |  |  |
| --- | --- | --- |
| * 1. **Stage III-IV Primary and Recurrent Epithelial Ovarian Cancer (EOC)** | **2017** | **2019**2 |
| Number of stage III-IV ovarian cancers treated in the center |  |  |
| Number or gynaecological oncologists in the centre |  |  |
| Proportion of primary debulking surgeries vs. NAC |  |  |
| Complete Resection Rate1 |  |  |
| * At the Primary Surgery |  |  |
| * After Neo-Adjuvant Chemotherapy |  |  |

**Part II – Evaluation of the Attendee of the Course**

|  |  |  |
| --- | --- | --- |
| * 1. **Stage III-IV Primary and Recurrent Epithelial Ovarian Cancer (EOC) surgeries performed by the attendee at the centre** | **2017** | **2019**2 |
| Number of stage III-IV ovarian cancers treated by the attendee |  |  |
| * Proportion of primary debulking surgeries |  |  |
| * Complete Resection Rate1 |  |  |
| * At the Primary Surgery |  |  |
| * After Neo-Adjuvant Chemotherapy |  |  |
| * 1. **Number of Specific Surgeries performed by the attendee** |  |  |
| Liver Mobilization |  |  |
| Diaphragm Stripping or Resection |  |  |
| Total Omentectomy |  |  |
| Splenectomy |  |  |
| Distal Pancreatectomy |  |  |
| Bowel surgery |  |  |
| Total number of other surgical procedures *(Dissection of Porta Hepatis or Celiac Trunk, Stomach Mobilization or Resection, Ureteral Reconstruction and Urinary Conduits, Video Assisted Thoracoscopic Surgery (VATS) and/or Cardiophrenic LND*) |  |  |

1 Complete abdominal surgical resection is defined by the absence of remaining macroscopic lesions after careful exploration of the abdomen. Surgery can be decided upfront, or planned after neoadjuvant chemotherapy. Refer to ESGO Quality Indicators on Surgery in Advanced Staged EOC for more details (see <https://guidelines.esgo.org/ovarian-cancer/quality-indicators/indicators/>)

2This data will be collected prospectively in 1 year after the Course

**\*Attendee inclusion criterium:**

Completion of training in gynaecologic oncology or at least 5 years’ experience in gynaecologic oncology.

Assessment form during the application process, along with your CV and Motivation statement will serve for the scoring and selection of course participants.

This Application form properly filled in should be sent to: <elenaulrikh@yandex.ru>